Clinical trial · Observational
Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy
Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy and Postoperative Adjuvant Chemotherapy Benefit in Advanced Gastric Cancer: a Two-center Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| response to neoadjuvant chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- good response to neoadjuvant chemotherapy (GRNC)
- description
- Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC)
- interventionNames
- Other: response to neoadjuvant chemotherapy
- label
- poor response to neoadjuvant chemotherapy (PRNC)
- description
- TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
- interventionNames
- Other: response to neoadjuvant chemotherapy
Primary outcomes (2)
- measure
- AUC for ICSS
- timeFrame
- 2022-01-01 to 2022-07-31
- description
- The predictive performance of imaging change scoring system before and after neoadjuvant chemotherapy (ICSS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection Exclusion Criteria: * Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.
References
Publications (0)
Data not yet available